IP Library Granted Patent US 7,785,816
Granted Patent B2
US 7,785,816 · App. 11/837,333 · Granted Aug 31, 2010

Antibodies against cancer antigen TMEFF2 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,816
App. No.
11/837,333
Granted
Aug 31, 2010
Kind
B2
Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Claims (4)

1. A method of detecting a prostate cancer cell expressing TMEFF2 in a biological sample from a patient, the method comprising contacting the biological sample with an antibody that competitively inhibits binding of TMEFF2#19 to TMEFF2, wherein the antibody comprises the CDR sequences present in the heavy chain variable sequence of SEQ ID NO: 26 and the light chain variable region sequence of SEQ ID NO: 34.

2. The method of claim 1 , wherein the antibody is further conjugated to a fluorescent label.

3. A method of detecting a cancer cell expressing TMEFF2 in a biological sample from a patient, the method comprising contacting the biological sample with an antibody comprising SEQ ID NO: 26 and SEQ ID NO: 34.

4. The method of claim 1 , wherein the antibody comprises SEQ ID NOs: 26 and 34.

Assignments (3)
CHANGE OF NAME Recorded Dec 20, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 031834/0936 →
CHANGE OF NAME Recorded Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0269 →